Merck’s Keytruda Pushes Towards Earlier Stages of Cervical Cancer with Phase III Data

Merck on Friday released additional data from its Phase III KEYNOTE-A18 study, demonstrating that its blockbuster PD-1 inhibitor Keytruda (pembrolizumab) can significantly improve overall survival when used to treat patients with newly diagnosed high-risk locally advanced cervical cancer.